Payment overview · 2025
General Payments
$22,294.30
249 reported records · 30 companies
Healthcare provider profile · identity verified
Stella Ilyayeva, MD
Allopathic & Osteopathic Physicians|Internal Medicine|Endocrinology, Diabetes & Metabolism · REGO PARK, NY · NPI 1619082625
Verified facts
What the public records show
CMS Open Payments records show Stella Ilyayeva, MD received $22,294.30 in general payments during 2025 across 249 reported records.
Amgen Inc. accounted for 56.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 38 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Afrezza, Jardiance, Kerendia, Mounjaro, Ozempic, Prolia, Rybelsus, Tepezza.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 121 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 96 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 2159 claims for Synthroid by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 361 claims for Prolia by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TEPEZZA as an associated drug or biological on 32661 records involving 9684 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Tepezza by this doctor in 2024.
Azurity Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported EDARBYCLOR as an associated drug or biological on 283 records involving 215 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Edarbyclor by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 196 claims for Kerendia by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 5520 claims for Jardiance by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNJARDY as an associated drug or biological on 33 records involving 33 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Synjardy by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 5520 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 1720 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 1736 claims for Trulicity by this doctor in 2024.
Mannkind Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AFREZZA as an associated drug or biological on 10645 records involving 3625 distinct recipient NPIs. Public Medicare Part D data also shows 587 claims for Afrezza by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Fiasp as an associated drug or biological on 15 records involving 15 distinct recipient NPIs. Public Medicare Part D data also shows 102 claims for Fiasp by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 3061 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 132 claims for Rybelsus by this doctor in 2024.
SANOFI-AVENTIS U.S. LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LANTUS as an associated drug or biological on 12 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Lantus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $12,528.74 | 56.2% | 42 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $3,903.08 | 17.5% | 13 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $1,052.04 | 4.7% | 8 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $656.26 | 2.9% | 18 | 2025 |
| Amphastar Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $637.01 | 2.9% | 41 | 2025 |
| Mannkind Corporation | Unresolved — no canonical attribution shown | $600.51 | 2.7% | 22 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $348.19 | 1.6% | 10 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $339.35 | 1.5% | 14 | 2025 |
| Intra-Sana Laboratories | Unresolved — no canonical attribution shown | $328.14 | 1.5% | 12 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $243.30 | 1.1% | 9 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $211.26 | 0.9% | 4 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$198.19 | 0.9% | 8 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $176.90 | 0.8% | 9 | 2025 |
| Ascendis Pharma Endocrinology Inc | Unresolved — no canonical attribution shown | $157.95 | 0.7% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $153.69 | 0.7% | 10 | 2025 |
| Tandem Diabetes Care, Inc. | Unresolved — no canonical attribution shown | $126.03 | 0.6% | 3 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $113.45 | 0.5% | 2 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $89.83 | 0.4% | 4 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $85.73 | 0.4% | 4 | 2025 |
| Ascensia Diabetes Care Us Inc. | Unresolved — no canonical attribution shown | $71.74 | 0.3% | 1 | 2025 |
| Insulet Corporation | Unresolved — no canonical attribution shown | $59.46 | 0.3% | 2 | 2025 |
| Rhythm Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $36.01 | 0.2% | 2 | 2025 |
| Chiesi USA, Inc. | Unresolved — no canonical attribution shown | $28.57 | 0.1% | 1 | 2025 |
| Azurity Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $25.06 | 0.1% | 1 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $24.52 | 0.1% | 1 | 2025 |
| Amneal Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $23.91 | 0.1% | 1 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $22.79 | 0.1% | 1 | 2025 |
| Ionis Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $18.42 | 0.1% | 1 | 2025 |
| SCILEX PHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $18.19 | 0.1% | 1 | 2025 |
| CeQur Corporation | Unresolved — no canonical attribution shown | $15.98 | 0.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $10,043.75 | 9 |
| Food and Beverage | $6,177.73 | 232 |
| Consulting Fee | $4,675.00 | 4 |
| Travel and Lodging | $1,397.82 | 4 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| TEPEZZA Normalized: tepezza |
Biological | Amgen Inc. | $6,374.64 | 22 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $6,130.49 | 19 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $4,796.83 | 14 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $656.26 | 18 | 2025 |
Source payment records
|
|||||
| AFREZZA Normalized: afrezza |
Drug | Mannkind Corporation | $600.51 | 22 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $348.19 | 10 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $339.35 | 14 | 2025 |
Source payment records
|
|||||
| GLYCATE Normalized: glycate |
Drug | Intra-Sana Laboratories | $328.14 | 12 | 2025 |
Source payment records
|
|||||
| RELTONE 200 MG Normalized: reltone 200 mg |
Drug | Intra-Sana Laboratories | $328.14 | 12 | 2025 |
Source payment records
|
|||||
| RELTONE 400 MG Normalized: reltone 400 mg |
Drug | Intra-Sana Laboratories | $328.14 | 12 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $243.30 | 9 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $213.40 | 11 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $199.66 | 8 | 2025 |
Source payment records
|
|||||
| INCEPTIV Normalized: inceptiv |
Device | Medtronic, Inc. | $198.19 | 8 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $166.24 | 8 | 2025 |
Source payment records
|
|||||
| Yorvipath Normalized: yorvipath |
Drug | Ascendis Pharma Endocrinology Inc | $157.95 | 3 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $153.69 | 10 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $137.52 | 6 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $137.52 | 6 | 2025 |
Source payment records
|
|||||
| DEXCOM G7 GSS (161) Normalized: dexcom g7 gss 161 |
Medical Supply | Dexcom, Inc. | $130.00 | 1 | 2025 |
Source payment records
|
|||||
| DEXCOM STELO GLUCOSE BIOSENSOR Normalized: dexcom stelo glucose biosensor |
Not specified | Dexcom, Inc. | $130.00 | 1 | 2025 |
Source payment records
|
|||||
| t:slim X2 Insulin Pump with Control-IQ Normalized: t slim x2 insulin pump with control iq |
Device | Tandem Diabetes Care, Inc. | $126.03 | 3 | 2025 |
Source payment records
|
|||||
| Symbravo Normalized: symbravo |
Drug | Axsome Therapeutics, Inc. | $113.45 | 2 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $89.83 | 4 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $85.73 | 4 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $81.26 | 3 | 2025 |
Source payment records
|
|||||
| Omnipod Normalized: omnipod |
Device | Insulet Corporation | $59.46 | 2 | 2025 |
Source payment records
|
|||||
| IMCIVREE Normalized: imcivree |
Drug | Rhythm Pharmaceuticals, Inc. | $36.01 | 2 | 2025 |
Source payment records
|
|||||
| MYCAPSSA Normalized: mycapssa |
Drug | Chiesi USA, Inc. | $28.57 | 1 | 2025 |
Source payment records
|
|||||
| AZMIRO Normalized: azmiro |
Drug | Azurity Pharmaceuticals, Inc. | $25.06 | 1 | 2025 |
Source payment records
|
|||||
| Lenvima Normalized: lenvima |
Drug | Eisai Inc. | $24.52 | 1 | 2025 |
Source payment records
|
|||||
| UNITHROID Normalized: unithroid |
Drug | Amneal Pharmaceuticals LLC | $23.91 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $23.61 | 1 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $22.79 | 1 | 2025 |
Source payment records
|
|||||
| TRYNGOLZA Normalized: tryngolza |
Drug | Ionis Pharmaceuticals, Inc. | $18.42 | 1 | 2025 |
Source payment records
|
|||||
| ZTLido Normalized: ztlido |
Drug | SCILEX PHARMACEUTICALS INC. | $18.19 | 1 | 2025 |
Source payment records
|
|||||
| CeQur Simplicity Normalized: cequr simplicity |
Device | CeQur Corporation | $15.98 | 1 | 2025 |
Source payment records
|
|||||
| RECORLEV Normalized: recorlev |
Drug | Xeris Pharmaceuticals, Inc. | $10.66 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| AFREZZA afrezza |
2025 | Afrezza | 2024 | 587 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 5520 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 196 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 1720 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 3061 | exact normalized | Medicare Part D |
| PROLIA prolia |
2025 | Prolia | 2024 | 361 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 132 | exact normalized | Medicare Part D |
| TEPEZZA tepezza |
2025 | Tepezza | 2024 | 21 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
121 | 20 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
96 | 26 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
2159 | 323 |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
361 | 222 |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | TEPEZZA open payments reported associated product |
CMS Open Payments — General Payments 32661 supporting records · 9684 recipient NPIs · example record 1226871638 |
Tepezza · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| Azurity Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | EDARBYCLOR open payments reported associated product |
CMS Open Payments — General Payments 283 supporting records · 215 recipient NPIs · example record 1242666846 |
Edarbyclor · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
196 | 34 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
5520 | 1051 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | SYNJARDY open payments reported associated product |
CMS Open Payments — General Payments 33 supporting records · 33 recipient NPIs · example record 1222725005 |
Synjardy · 2024 Exact normalized brand match · 1 Part D row |
46 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
5520 | 1051 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
1720 | 316 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
1736 | 340 |
| Mannkind Corporation Exact reporting entity; no affiliate inference |
2025 | AFREZZA open payments reported associated product |
CMS Open Payments — General Payments 10645 supporting records · 3625 recipient NPIs · example record 1250869202 |
Afrezza · 2024 Exact normalized brand match · 1 Part D row |
587 | 200 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Fiasp open payments reported associated product |
CMS Open Payments — General Payments 15 supporting records · 15 recipient NPIs · example record 1188262936 |
Fiasp · 2024 Exact normalized brand match · 1 Part D row |
102 | 19 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
3061 | 582 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
132 | 27 |
| SANOFI-AVENTIS U.S. LLC Exact reporting entity; no affiliate inference |
2025 | LANTUS open payments reported associated product |
CMS Open Payments — General Payments 12 supporting records · 11 recipient NPIs · example record 1233196856 |
Lantus · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Jardiance | Empagliflozin | 5520 | 1051 |
| Metformin Hcl | Metformin Hcl | 3539 | 766 |
| Ozempic | Semaglutide | 3061 | 582 |
| Pioglitazone Hcl | Pioglitazone Hcl | 2974 | 610 |
| Glimepiride | Glimepiride | 2372 | 500 |
| Glipizide | Glipizide | 2209 | 429 |
| Levothyroxine Sodium | Levothyroxine Sodium | 2197 | 404 |
| Synthroid | Levothyroxine Sodium | 2159 | 323 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 1853 | 302 |
| Trulicity | Dulaglutide | 1736 | 340 |
| Mounjaro | Tirzepatide | 1720 | 316 |
| Atorvastatin Calcium | Atorvastatin Calcium | 1682 | 414 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 1494 | 473 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 1358 | 301 |
| Metoprolol Succinate | Metoprolol Succinate | 1230 | 301 |
| Repaglinide | Repaglinide | 1227 | 269 |
| Farxiga | Dapagliflozin Propanediol | 1165 | 234 |
| Losartan Potassium | Losartan Potassium | 933 | 249 |
| Amlodipine Besylate | Amlodipine Besylate | 928 | 243 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 925 | 248 |
| Januvia | Sitagliptin Phosphate | 877 | 165 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 861 | 211 |
| Vascepa | Icosapent Ethyl | 814 | 135 |
| Methimazole | Methimazole | 756 | 134 |
| Metformin Hcl Er | Metformin Hcl | 739 | 214 |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 702 | 176 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 702 | 177 |
| Single Use Swab | Alcohol Antiseptic Pads | 656 | 235 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 653 | 185 |
| Jentadueto | Linagliptin/Metformin Hcl | 597 | 84 |
| Afrezza | Insulin Regular, Human | 587 | 200 |
| Simvastatin | Simvastatin | 550 | 127 |
| Escitalopram Oxalate | Escitalopram Oxalate | 530 | 126 |
| Gabapentin | Gabapentin | 524 | 151 |
| Omnipod 5 Dexg7g6 Pods (Gen 5) | Insulin Pump Cart,auto,bt,g6/7 | 519 | 80 |
| Easy Touch Alcohol Prep Pads | Alcohol Antiseptic Pads | 509 | 154 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 502 | 128 |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 453 | 141 |
| Tradjenta | Linagliptin | 424 | 74 |
| Alendronate Sodium | Alendronate Sodium | 382 | 90 |
| Novolog Flexpen | Insulin Aspart | 368 | 99 |
| Prolia | Denosumab | 361 | 222 |
| Alcohol Pads | Alcohol Antiseptic Pads | 350 | 122 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 336 | 92 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 273 | 121 |
| Novolog | Insulin Aspart | 272 | 54 |
| Lisinopril | Lisinopril | 270 | 74 |
| Metformin Er Gastric | Metformin Hcl | 266 | 49 |
| Metoprolol Tartrate | Metoprolol Tartrate | 261 | 56 |
| Clopidogrel | Clopidogrel Bisulfate | 257 | 67 |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 251 | 84 |
| Tresiba Flextouch U-100 | Insulin Degludec | 248 | 78 |
| Humalog Mix 75-25 Kwikpen | Insulin Lispro Protamin/Lispro | 247 | 45 |
| Gvoke Hypopen 2-Pack | Glucagon | 231 | 104 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 226 | 52 |
| Steglatro | Ertugliflozin Pidolate | 219 | 41 |
| Carvedilol | Carvedilol | 208 | 59 |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 208 | 76 |
| Kerendia | Finerenone | 196 | 34 |
| Omnipod Dash Pods (Gen 4) | Insulin Pump Cart,cont Inf,bt | 195 | 34 |
| Repatha Sureclick | Evolocumab | 195 | 26 |
| Omeprazole | Omeprazole | 179 | 56 |
| Furosemide | Furosemide | 176 | 51 |
| Ibandronate Sodium | Ibandronate Sodium | 174 | 41 |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 158 | 34 |
| Atenolol | Atenolol | 153 | 35 |
| Enalapril Maleate | Enalapril Maleate | 141 | 33 |
| Ezetimibe | Ezetimibe | 140 | 41 |
| Calcitriol | Calcitriol | 139 | 24 |
| Glyburide | Glyburide | 134 | 25 |
| Valsartan | Valsartan | 133 | 35 |
| Rybelsus | Semaglutide | 132 | 27 |
| Pro Comfort Alcohol Pads | Alcohol Antiseptic Pads | 131 | 41 |
| Fenofibrate | Fenofibrate,micronized | 130 | 28 |
| Tamsulosin Hcl | Tamsulosin Hcl | 126 | 29 |
| Pravastatin Sodium | Pravastatin Sodium | 124 | 26 |
| Ramipril | Ramipril | 124 | 27 |
| Sertraline Hcl | Sertraline Hcl | 124 | 29 |
| Terconazole | Terconazole | 123 | 83 |
| Creon | Lipase/Protease/Amylase | 121 | 20 |
| Fenofibrate | Fenofibrate Nanocrystallized | 121 | 28 |
| Humalog Kwikpen U-100 | Insulin Lispro | 120 | 37 |
| Fluconazole | Fluconazole | 119 | 74 |
| Dapagliflozin | Dapagliflozin Propanediol | 118 | 53 |
| Humalog | Insulin Lispro | 117 | 22 |
| Olmesartan-Amlodipine-Hctz | Olmesartan/Amlodipin/Hcthiazid | 117 | 31 |
| Fenofibrate | Fenofibrate | 114 | 25 |
| Hydralazine Hcl | Hydralazine Hcl | 112 | 36 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 112 | 33 |
| Alcohol Swabs | Alcohol Antiseptic Pads | 105 | 40 |
| Icosapent Ethyl | Icosapent Ethyl | 105 | 39 |
| Dexilant | Dexlansoprazole | 104 | 17 |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 104 | 33 |
| Pantoprazole Sodium | Pantoprazole Sodium | 103 | 29 |
| Fiasp | Insulin Aspart (Niacinamide) | 102 | 19 |
| Hydrochlorothiazide | Hydrochlorothiazide | 100 | 33 |
| Ultra-Fine Micro Pen Needle | Pen Needle, Diabetic | 98 | 35 |
| Linzess | Linaclotide | 96 | 26 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 87 | 25 |
| Azithromycin | Azithromycin | 86 | 48 |
| Eliquis | Apixaban | 86 | 28 |
| Tresiba Flextouch U-200 | Insulin Degludec | 86 | 28 |
| Glumetza | Metformin Hcl | 84 | 18 |
| Dexlansoprazole Dr | Dexlansoprazole | 81 | 13 |
| Insulin Aspart Flexpen | Insulin Aspart | 80 | 26 |
| Insulin Lispro Protamine Mix | Insulin Lispro Protamin/Lispro | 80 | 22 |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 75 | 18 |
| Evenity (2 Syringes) | Romosozumab-Aqqg | 71 | 15 |
| Novofine 32 | Pen Needle, Diabetic | 71 | 27 |
| Hydrocortisone | Hydrocortisone | 70 | 15 |
| Insulin Lispro | Insulin Lispro | 70 | 20 |
| Famotidine | Famotidine | 69 | 16 |
| Omeprazole-Sodium Bicarbonate | Omeprazole/Sodium Bicarbonate | 67 | 19 |
| Humalog Kwikpen U-200 | Insulin Lispro | 66 | 12 |
| Testosterone Cypionate | Testosterone Cypionate | 64 | 18 |
| Invokana | Canagliflozin | 62 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 60 | 15 |
| Insulin Aspart Prot Mix 70-30 | Insulin Aspart Prot/Insuln Asp | 58 | 36 |
| Spironolactone | Spironolactone | 58 | 19 |
| Alcohol Swab | Alcohol Antiseptic Pads | 56 | 27 |
| Easy Comfort Pen Needle | Pen Needle, Diabetic | 54 | 23 |
| Alogliptin-Metformin | Alogliptin Benz/Metformin Hcl | 53 | 12 |
| Glipizide Er | Glipizide | 53 | 14 |
| Insulin Syringe | Syringe And Needle,insulin,1ml | 53 | 22 |
| Acarbose | Acarbose | 52 | suppressed |
| Bystolic | Nebivolol Hcl | 52 | suppressed |
| Benicar | Olmesartan Medoxomil | 50 | suppressed |
| Kapspargo Sprinkle | Metoprolol Succinate | 50 | 17 |
| Nifedipine Er | Nifedipine | 49 | 16 |
| Chlorthalidone | Chlorthalidone | 48 | suppressed |
| Ultracare Pen Needle | Pen Needle, Diabetic | 48 | 20 |
| Insulin Syringe | Syringe-Needle,insulin,0.5 Ml | 46 | 12 |
| Synjardy | Empagliflozin/Metformin Hcl | 46 | suppressed |
| Crestor | Rosuvastatin Calcium | 45 | 14 |
| Levemir Flexpen | Insulin Detemir | 43 | 15 |
| Zenpep | Lipase/Protease/Amylase | 43 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 41 | 13 |
| Nebivolol Hcl | Nebivolol Hcl | 41 | suppressed |
| Novolin 70-30 Flexpen | Insulin Nph Hum/Reg Insulin Hm | 41 | suppressed |
| Humalog Mix 50-50 Kwikpen | Insulin Lispro Protamin/Lispro | 40 | suppressed |
| Nexium | Esomeprazole Magnesium | 40 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 39 | suppressed |
| Omnipod 5 Dexg7g6 Intro(Gen 5) | Insulin Pmp Cart,aut,g6/7,cntr | 39 | 39 |
| Clonidine Hcl | Clonidine Hcl | 38 | suppressed |
| Admelog Solostar | Insulin Lispro | 36 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 35 | 30 |
| Edarbyclor | Azilsartan Med/Chlorthalidone | 35 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 35 | 11 |
| Admelog | Insulin Lispro | 33 | suppressed |
| Benicar Hct | Olmesartan/Hydrochlorothiazide | 33 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 33 | 17 |
| Pentips Pen Needle | Pen Needle, Diabetic | 33 | 15 |
| Ultra-Fine Original Pen Needle | Pen Needle, Diabetic | 32 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 31 | suppressed |
| Easy Comfort Pen Needles | Pen Needle, Diabetic | 30 | 16 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 30 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 29 | 11 |
| Cinacalcet Hcl | Cinacalcet Hcl | 28 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 28 | suppressed |
| Semglee (Yfgn) Pen | Insulin Glargine-Yfgn | 28 | 15 |
| Victoza 3-Pak | Liraglutide | 28 | suppressed |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 28 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 27 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 27 | 20 |
| Comfort Ez Pro Safety Pen Ndl | Pen Needle, Diabetic, Safety | 26 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 26 | suppressed |
| Gemfibrozil | Gemfibrozil | 26 | suppressed |
| Pro Comfort Pen Needle | Pen Needle, Diabetic | 26 | suppressed |
| True Comfort Pro Alcohol Pads | Alcohol Antiseptic Pads | 26 | 18 |
| True Comfort Safety Pen Needle | Pen Needle, Diabetic, Safety | 26 | 14 |
| Welchol | Colesevelam Hcl | 26 | suppressed |
| Lidocaine | Lidocaine | 25 | suppressed |
| Pen Needle | Pen Needle, Diabetic | 25 | 14 |
| Ulticare Pen Needle | Pen Needle, Diabetic | 25 | suppressed |
| Allopurinol | Allopurinol | 24 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 24 | suppressed |
| Gvoke | Glucagon | 24 | 12 |
| Nitroglycerin | Nitroglycerin | 24 | 11 |
| Tirosint | Levothyroxine Sodium | 24 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 24 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 23 | suppressed |
| Ketoconazole | Ketoconazole | 23 | 11 |
| Livalo | Pitavastatin Calcium | 23 | suppressed |
| Unifine Pentips | Pen Needle, Diabetic | 23 | 12 |
| Alogliptin | Alogliptin Benzoate | 22 | suppressed |
| Easy-Touch Insulin Syringe | Syringe And Needle,insulin,1ml | 22 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 22 | suppressed |
| Xarelto | Rivaroxaban | 22 | suppressed |
| Humalog Mix 75-25 | Insulin Lispro Protamin/Lispro | 21 | suppressed |
| Irbesartan | Irbesartan | 21 | suppressed |
| Pitavastatin Calcium | Pitavastatin Calcium | 21 | suppressed |
| Praluent Pen | Alirocumab | 21 | suppressed |
| Tepezza | Teprotumumab-Trbw | 21 | suppressed |
| Alprazolam | Alprazolam | 20 | suppressed |
| Bydureon Bcise | Exenatide Microspheres | 20 | suppressed |
| Telmisartan | Telmisartan | 20 | suppressed |
| Albendazole | Albendazole | 19 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 19 | suppressed |
| Brilinta | Ticagrelor | 19 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 19 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 19 | suppressed |
| Cycloset | Bromocriptine Mesylate | 18 | suppressed |
| Finasteride | Finasteride | 18 | suppressed |
| Folic Acid | Folic Acid | 18 | suppressed |
| Glyxambi | Empagliflozin/Linagliptin | 18 | suppressed |
| Lovastatin | Lovastatin | 18 | suppressed |
| Ranolazine Er | Ranolazine | 18 | suppressed |
| Repatha Syringe | Evolocumab | 18 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 17 | suppressed |
| Meloxicam | Meloxicam | 17 | suppressed |
| Nystatin | Nystatin | 17 | 12 |
| Azelastine Hcl | Azelastine Hcl | 16 | suppressed |
| Insulin Aspart | Insulin Aspart | 16 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 16 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 16 | suppressed |
| Ursodiol | Ursodiol | 16 | suppressed |
| Veo Insulin Syringe | Syringe And Needle,insulin,1ml | 16 | suppressed |
| Insulin Degludec Pen (U-100) | Insulin Degludec | 15 | suppressed |
| Propylthiouracil | Propylthiouracil | 15 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 14 | 12 |
| Potassium Chloride | Potassium Chloride | 14 | suppressed |
| Pure Comfort Alcohol Pad | Alcohol Antiseptic Pads | 14 | suppressed |
| Advair Diskus | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 13 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 13 | suppressed |
| Digoxin | Digoxin | 13 | suppressed |
| Easy Touch | Syringe-Needle,insulin,0.5 Ml | 13 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 13 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 12 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 12 | suppressed |
| Cequr Simplicity | Bolus Insulin Pump, 200 Unit | 12 | suppressed |
| Clotrimazole | Clotrimazole | 12 | suppressed |
| Colchicine | Colchicine | 12 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 12 | suppressed |
| Humulin 70/30 Kwikpen | Insulin Nph Hum/Reg Insulin Hm | 12 | suppressed |
| Ibuprofen | Ibuprofen | 12 | suppressed |
| Insulin Glargine Solostar | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Jublia | Efinaconazole | 12 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 12 | suppressed |
| Lokelma | Sodium Zirconium Cyclosilicate | 12 | suppressed |
| Neomycin-Polymyxin-Dexameth | Neomycin/Polymyxin B/Dexametha | 12 | suppressed |
| Novofine Plus | Pen Needle, Diabetic | 12 | suppressed |
| Ultra Comfort | Syringe And Needle,insulin,1ml | 12 | suppressed |
| Clonidine | Clonidine | 11 | suppressed |
| Entresto | Sacubitril/Valsartan | 11 | suppressed |
| Fosinopril Sodium | Fosinopril Sodium | 11 | suppressed |
| Glucagon Emergency Kit | Glucagon | 11 | suppressed |
| Indapamide | Indapamide | 11 | suppressed |
| Insulin Syringe | Syrge-Ndl,ins 0.3 Ml Half Mark | 11 | suppressed |
| Lipitor | Atorvastatin Calcium | 11 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 11 | suppressed |
| Uloric | Febuxostat | 11 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $22,294.30 · 249 records | Amgen Inc. | AFREZZA, AZMIRO, CeQur Simplicity, DEXCOM G7 GSS (161), DEXCOM STELO GLUCOSE BIOSENSOR, Dexcom G6 Transmitter, EVENITY, FREESTYLE LIBRE 3, GLYCATE, GVOKE HYPOPEN, IMCIVREE, INCEPTIV, JARDIANCE, Kerendia, Korlym, Lenvima, MOUNJARO, MYCAPSSA, Omnipod, Ozempic, PROLIA, RECORLEV, RELTONE 200 MG, RELTONE 400 MG, REPATHA, Rybelsus, Symbravo, TEPEZZA, TRYNGOLZA, TZIELD, UBRELVY, UNITHROID, VOQUEZNA, Veozah, Yorvipath, ZEPBOUND, ZTLido, t:slim X2 Insulin Pump with Control-IQ | 17 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Afrezza play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error